Phase 1, open label, multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CP 751,871 in patients with advanced solid tumors.

Trial Profile

Phase 1, open label, multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CP 751,871 in patients with advanced solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2014

At a glance

  • Drugs Figitumumab (Primary)
  • Indications Ewing's sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top